King's College London

Research portal

TRICALS: creating a highway toward a cure

Research output: Contribution to journalReview article

Standard

TRICALS : creating a highway toward a cure. / van Eijk, Ruben P A; Kliest, Tessa; McDermott, Christopher J; Roes, Kit C B; Van Damme, Philip; Chio, Adriano; Weber, Markus; Ingre, Caroline; Corcia, Philippe; Povedano, Mònica; Reviers, Evy; van Es, Michael A; Al-Chalabi, Ammar; Hardiman, Orla; van den Berg, Leonard H.

In: Amyotrophic lateral sclerosis & frontotemporal degeneration, 09.07.2020, p. 1-6.

Research output: Contribution to journalReview article

Harvard

van Eijk, RPA, Kliest, T, McDermott, CJ, Roes, KCB, Van Damme, P, Chio, A, Weber, M, Ingre, C, Corcia, P, Povedano, M, Reviers, E, van Es, MA, Al-Chalabi, A, Hardiman, O & van den Berg, LH 2020, 'TRICALS: creating a highway toward a cure', Amyotrophic lateral sclerosis & frontotemporal degeneration, pp. 1-6. https://doi.org/10.1080/21678421.2020.1788092

APA

van Eijk, R. P. A., Kliest, T., McDermott, C. J., Roes, K. C. B., Van Damme, P., Chio, A., Weber, M., Ingre, C., Corcia, P., Povedano, M., Reviers, E., van Es, M. A., Al-Chalabi, A., Hardiman, O., & van den Berg, L. H. (2020). TRICALS: creating a highway toward a cure. Amyotrophic lateral sclerosis & frontotemporal degeneration, 1-6. https://doi.org/10.1080/21678421.2020.1788092

Vancouver

van Eijk RPA, Kliest T, McDermott CJ, Roes KCB, Van Damme P, Chio A et al. TRICALS: creating a highway toward a cure. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2020 Jul 9;1-6. https://doi.org/10.1080/21678421.2020.1788092

Author

van Eijk, Ruben P A ; Kliest, Tessa ; McDermott, Christopher J ; Roes, Kit C B ; Van Damme, Philip ; Chio, Adriano ; Weber, Markus ; Ingre, Caroline ; Corcia, Philippe ; Povedano, Mònica ; Reviers, Evy ; van Es, Michael A ; Al-Chalabi, Ammar ; Hardiman, Orla ; van den Berg, Leonard H. / TRICALS : creating a highway toward a cure. In: Amyotrophic lateral sclerosis & frontotemporal degeneration. 2020 ; pp. 1-6.

Bibtex Download

@article{8685bbbdf58144218065d40d597bff34,
title = "TRICALS: creating a highway toward a cure",
abstract = "A change in our current approach toward drug development is required to improve the likelihood of finding effective treatment for patients with amyotrophic lateral sclerosis (ALS). The aim of the Treatment Research Initiative to Cure ALS (TRICALS) is to extend the collective effort with industry and consolidate drug development paths. TRICALS has begun a series of meetings on how to best move the field forward collaboratively, thereby addressing five major topics in ALS clinical trials: (1) preclinical research, (2) biomarker development, (3) eligibility criteria, (4) efficacy endpoints and (5) innovative trial design. There is an appetite for ongoing discussions of these major topics in clinical trials between representatives from academia, patient advocacy groups, industry partners and funding bodies. Industry is open to fundamentally change drug development for ALS and shorten the time to effective therapy for patients by implementing promising innovations in biomarker development, trial design, and patient selection. There is however, a pressing need from all stakeholders for regulatory discussions and amendments of current guidelines to successfully adopt innovation in future clinical development lines.",
keywords = "Clinical trial design, biomarkers, guidelines, preclinical",
author = "{van Eijk}, {Ruben P A} and Tessa Kliest and McDermott, {Christopher J} and Roes, {Kit C B} and {Van Damme}, Philip and Adriano Chio and Markus Weber and Caroline Ingre and Philippe Corcia and M{\`o}nica Povedano and Evy Reviers and {van Es}, {Michael A} and Ammar Al-Chalabi and Orla Hardiman and {van den Berg}, {Leonard H}",
year = "2020",
month = jul,
day = "9",
doi = "10.1080/21678421.2020.1788092",
language = "English",
pages = "1--6",
journal = "Amyotrophic lateral sclerosis & frontotemporal degeneration",
issn = "2167-8421",
publisher = "Taylor & Francis",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - TRICALS

T2 - creating a highway toward a cure

AU - van Eijk, Ruben P A

AU - Kliest, Tessa

AU - McDermott, Christopher J

AU - Roes, Kit C B

AU - Van Damme, Philip

AU - Chio, Adriano

AU - Weber, Markus

AU - Ingre, Caroline

AU - Corcia, Philippe

AU - Povedano, Mònica

AU - Reviers, Evy

AU - van Es, Michael A

AU - Al-Chalabi, Ammar

AU - Hardiman, Orla

AU - van den Berg, Leonard H

PY - 2020/7/9

Y1 - 2020/7/9

N2 - A change in our current approach toward drug development is required to improve the likelihood of finding effective treatment for patients with amyotrophic lateral sclerosis (ALS). The aim of the Treatment Research Initiative to Cure ALS (TRICALS) is to extend the collective effort with industry and consolidate drug development paths. TRICALS has begun a series of meetings on how to best move the field forward collaboratively, thereby addressing five major topics in ALS clinical trials: (1) preclinical research, (2) biomarker development, (3) eligibility criteria, (4) efficacy endpoints and (5) innovative trial design. There is an appetite for ongoing discussions of these major topics in clinical trials between representatives from academia, patient advocacy groups, industry partners and funding bodies. Industry is open to fundamentally change drug development for ALS and shorten the time to effective therapy for patients by implementing promising innovations in biomarker development, trial design, and patient selection. There is however, a pressing need from all stakeholders for regulatory discussions and amendments of current guidelines to successfully adopt innovation in future clinical development lines.

AB - A change in our current approach toward drug development is required to improve the likelihood of finding effective treatment for patients with amyotrophic lateral sclerosis (ALS). The aim of the Treatment Research Initiative to Cure ALS (TRICALS) is to extend the collective effort with industry and consolidate drug development paths. TRICALS has begun a series of meetings on how to best move the field forward collaboratively, thereby addressing five major topics in ALS clinical trials: (1) preclinical research, (2) biomarker development, (3) eligibility criteria, (4) efficacy endpoints and (5) innovative trial design. There is an appetite for ongoing discussions of these major topics in clinical trials between representatives from academia, patient advocacy groups, industry partners and funding bodies. Industry is open to fundamentally change drug development for ALS and shorten the time to effective therapy for patients by implementing promising innovations in biomarker development, trial design, and patient selection. There is however, a pressing need from all stakeholders for regulatory discussions and amendments of current guidelines to successfully adopt innovation in future clinical development lines.

KW - Clinical trial design

KW - biomarkers

KW - guidelines

KW - preclinical

UR - http://www.scopus.com/inward/record.url?scp=85087798217&partnerID=8YFLogxK

U2 - 10.1080/21678421.2020.1788092

DO - 10.1080/21678421.2020.1788092

M3 - Review article

C2 - 32643415

SP - 1

EP - 6

JO - Amyotrophic lateral sclerosis & frontotemporal degeneration

JF - Amyotrophic lateral sclerosis & frontotemporal degeneration

SN - 2167-8421

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454